CA Patent

CA2551611C — Thiazole derivatives for treating or preventing parkinson's disease

Assigned to Individual · Expires 2013-06-25 · 13y expired

What this patent protects

There are provided compounds of formula (IA): (see formula IA) These compounds are adenosine A2A receptor antagonists useful for the treatment and prevention of a central nervous system disease such as Parkinson's disease.

USPTO Abstract

There are provided compounds of formula (IA): (see formula IA) These compounds are adenosine A2A receptor antagonists useful for the treatment and prevention of a central nervous system disease such as Parkinson's disease.

Drugs covered by this patent

avatrombopag-maleate (AVATROMBOPAG MALEATE)

Patent Metadata

Patent number: CA2551611C
Jurisdiction: CA
Classification: —
Expires: 2013-06-25
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.